Match!
Gregory Y.H. Lip
University of Liverpool
CardiologyAtrial fibrillationStrokeDiabetes mellitusMedicine
3,332Publications
143H-index
122kCitations
What is this?
Publications 3383
Newest
#1Hanis Zulkifly (University of Birmingham)H-Index: 3
#2Paola Cheli (University of Birmingham)H-Index: 2
Last. Deirdre A. Lane (University of Liverpool)H-Index: 63
view all 6 authors...
Abstract Background Efficacy and safety of vitamin K antagonists (VKAs) is optimised in atrial fibrillation (AF) patients when the International Normalised Ratio (INR) is 2.0–3.0. Anticoagulation control comparing different ethnic groups is limited, although epidemiological studies suggest poorer INR control in non-white cohorts. Methods VKA control was assessed retrospectively by time-in-the-therapeutic range (TTR) (Rosendaal method) and percentage INR-in-range (PINRR) in 991 White, Afro-Caribb...
Source
Aims Undiagnosed atrial fibrillation (AF) accounts for 6% of all strokes, therefore early detection and treatment of the arrhythmia are paramount. Previous research has illustrated that the Microlife WatchBPO3 AFIB, an automated blood pressure (BP) monitor with an inbuilt AF algorithm, accurately detects permanent AF. Currently, limited data exist on whether the modified BP monitor is able to detect paroxysmal AF (PAF). Therefore, this study aims to assess the accuracy of the Microlife WatchBPO3...
Source
#1Thure Filskov Overvad (AAU: Aalborg University)H-Index: 13
#2Søren Due Andersen (AAU: Aalborg University)H-Index: 7
Last. Peter Brønnum Nielsen (AAU: Aalborg University)H-Index: 19
view all 7 authors...
Abstract Background Intracerebral hemorrhage is a devastating vascular event. Clinical factors prognostic of recurrence facilitating individualized post-bleeding patient management are sparsely described. We aimed to describe incidence of recurrence of intracerebral hemorrhage and explore the prognostic value of 25 clinical characteristics in patients with and without atrial fibrillation. Methods Cohort study of patients with incident intracerebral hemorrhage diagnosed from 2003 to 2016 identifi...
Source
#1Saad Javed (University of Liverpool)
#2Dhiraj Gupta (University of Liverpool)H-Index: 1
Last. Gregory Y.H. Lip (University of Liverpool)H-Index: 143
view all 3 authors...
Source
#1Kamilla Steensig (Aarhus University Hospital)H-Index: 2
#2Kevin Kris Warnakula Olesen (Aarhus University Hospital)H-Index: 6
Last. John W. Eikelboom (McMaster University)H-Index: 94
view all 11 authors...
ABSTRACT Patients without atrial fibrillation (AF) constitute approximately 75% of patients suffering thromboembolism and major adverse cardiovascular events (MACE), but evidence supporting risk stratification in these patients is sparse. We aimed to develop a risk prediction model for identification of patients without AF at high risk of first-time thromboembolic events. We included 72,381 coronary angiography patients without AF and without prior ischemic stroke or transient ischemic attack. T...
Source
#1Maxime BoidinH-Index: 1
#2Gregory Y.H. Lip (LJMU: Liverpool John Moores University)H-Index: 143
Last. Dick H. J. Thijssen (LJMU: Liverpool John Moores University)H-Index: 46
view all 3 authors...
Source
#1Monika KoziełH-Index: 1
#1Monika Kozieł (University of Liverpool)H-Index: 1
Last. Miney Paquette (Boehringer Ingelheim)H-Index: 6
view all 16 authors...
Background: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)). Methods: Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinua...
Source
#1Line Melgaard (AAU: Aalborg University)H-Index: 5
#2Martin Bach Jensen (AAU: Aalborg University)H-Index: 23
Last. Peter Brønnum Nielsen (AAU: Aalborg University)H-Index: 19
view all 6 authors...
AIMS The risks of thromboembolism and bleeding in patients with atrial fibrillation (AF) and valvular heart disease (VHD) are sparsely described. We described the risk of events in non-anticoagulated and anticoagulated patients with AF and VHD according to the EHRA classification, EHRA Type 1 and Type 2 VHD, and within subgroups of EHRA Type 1 and Type 2 VHD. METHODS AND RESULTS Cohort study of AF patients with coexisting VHD, identified in nationwide Danish registries from 2000-2018. Risk of th...
Source
#1Mauro Massussi (UNIPD: University of Padua)H-Index: 1
#2Andrea Scotti (UNIPD: University of Padua)H-Index: 3
Last. Riccardo Proietti (UNIPD: University of Padua)H-Index: 18
view all 4 authors...
Left ventricular thrombosis (LVT) is a major risk factor for systemic thromboembolism and might complicate both the acute and the chronic phase of ischemic heart disease after myocardial infarction and, less frequently, non-ischemic cardiomyopathies. The pathophysiology of thrombus formation is complex and involves the three aspects of Virchow's triad: blood stasis, prothrombotic state and tissue injury. Advances in technology have improved the detection rate of intracardiac thrombi, but several...
Source
#1Hani Essa (University of Liverpool)
#2Francesco Torella (University of Liverpool)H-Index: 22
Last. Gregory Y.H. Lip (University of Liverpool)H-Index: 143
view all 3 authors...
Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk ...
Source
12345678910